Harnessing the power of cells
We are working to create cell therapies for treating people living with degenerative diseases.
In diseases such as Parkinson’s disease and inherited retinal diseases, cells are lost or damaged and the body is unable to regenerate them.
BlueRock’s Approach
We use pluripotent stem cells (PSCs) to make highly specific cell types with the intention to replace those lost or damaged to disease. Pluripotent stem cells have the ability to self-renew or differentiate into specific cell types.
Our pipeline and approach primarily focus on induced pluripotent stem cells (iPSC).
iPSCs – or ‘blank canvas’ cells – can be reprogrammed into highly specific cell types. We take fully developed adult donor cells and utilize our proprietary reprogramming technology to reprogram them into iPSCs.
Bemdaneprocel, our investigative therapy for treating Parkinson’s disease, is derived from another type of PSC, human embryonic stem cells. If approved, bemdaneprocel will be used in the treatment of Parkinson’s disease.
Cell + Gene
Employing our cell+gene platform, we can engineer PSCs using gene editing technology when necessary to enhance their potential therapeutic effect and stability within the body.
Production at Scale
Our manufacturing teams produce a stable supply of cells for early and late-stage clinical trials. We are collaborating with our colleagues at Bayer to manufacture cell therapies at scale.
